Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аллергический ринит – актуальная проблема XXI века
Аллергический ринит – актуальная проблема XXI века
Дынева М.Е., Курбачева О.М. Аллергический ринит – актуальная проблема XXI века. Consilium Medicum. 2019; 21 (3): 65–68. DOI: 10.26442/20751753.2019.3.190268
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Аллергический ринит (AР) является одним из наиболее распространенных хронических заболеваний верхних дыхательных путей во всем мире. Несмотря на успехи в понимании механизмов аллергического воспаления, симптомы АР в большинстве случаев не контролируются полностью с помощью современных методов лечения. АР – предвестник и предрасполагающий фактор развития других респираторных заболеваний, одним из которых является бронхиальная астма. Поэтому так важно вовремя диагностировать АР и подобрать наиболее эффективные и современные препараты, которые не только помогут контролировать течение АР, но и улучшат качество жизни пациентов. Интраназальные глюкокортикостероиды рекомендуются в качестве 1-й линии терапии для пациентов с разной степенью тяжести АР. Опыт применения интраназального флутиказона пропионата в России и за рубежом свидетельствует об эффективности данного препарата при лечении различных форм АР как в качестве монотерапии, так и в комбинации с антигистаминными препаратами, деконгестантами.
Ключевые слова: аллергический ринит, аллергия, бронхиальная астма, интраназальные глюкокортикостероиды.
Ключевые слова: аллергический ринит, аллергия, бронхиальная астма, интраназальные глюкокортикостероиды.
________________________________________________
Allergic rhinitis (AR) is one of the most common chronic diseases of the upper respiratory tract throughout the world. Despite advances in understanding the mechanisms of allergic inflammation, the symptoms of AR in most cases are not completely controlled by modern methods of treatment. AR is a precursor and a predisposing factor for the development of other respiratory diseases, one of which is bronchial asthma. Therefore, it is important to diagnose AR in time and select the most effective and modern drugs that will not only help control the course of AR, but also improve the quality of life of patients. Intranasal glucocorticosteroids are recommended as first-line therapy for patients with varying severity of AR. The experience of using intranasal fluticasone propionate in Russia and abroad testifies to the effectiveness of this drug in the treatment of various forms of AR, both as mono-therapy and in combination with antihistamines and decongestants.
Key words: allergic rhinitis, allergy, bronchial asthma, intranasal glucocorticosteroids.
Key words: allergic rhinitis, allergy, bronchial asthma, intranasal glucocorticosteroids.
Полный текст
Список литературы
1. Katelaris CH, Lee BW, Potter PC et al. Prevalence and diversity of allergic rhinitis in regions of the world beyond Europe and North America. Clin Exper Allergy 2011; 42: 186–207. DOI: 10.1111/j.1365-2222.2011.03891.x
2. Cong Li, Shen Y, Wang J et al. Increased Expression of IL-1R8 and a Possible immunomodulatory role of its ligand IL-37 in allergic rhinitis patients. Int Immunopharmacol 2018; 60 (1): 152–9. DOI: 10.1016/j.intimp.2018.04.002
3. Курбачева О.М., Польнер С.А., Смирнов Д.С. Аллергический Ринит. Мед. совет. 2015; 3: 84–91.
[Kurbacheva O.M., Pol'ner S.A., Smirnov D.S. Allergicheskii Rinit. Med. sovet. 2015; 3: 84–91 (in Russian).]
4. Курбачева О.М. Аллерген-специфическая иммунотерапия. Рос. аллергологический журн. 2004; 2: 32–8.
[Kurbacheva O.M. Allergen-spetsificheskaia immunoterapiia. Ros. allergologicheskii zhurn. 2004; 2: 32–8 (in Russian).]
5. Павлова К.С. Новые вoзможности терапии аллергического ринита. Атмосфера. Пульмонология и аллергология. 2009; 3: 34–8.
[Pavlova K.S. Novye vozmozhnosti terapii allergicheskogo rinita. Atmosfera. Pul'monologiia i allergologiia. 2009; 3: 34–8 (in Russian).]
6. Чичкова Н. Бронхиальная астма и полипозный риносинусит : особенности клинического течения и тактика ведения больных. Астма и аллергия. 2015; 1: 19–22.
[Chichkova N. Bronkhial'naia astma i polipoznyi rinosinusit: osobennosti klinicheskogo techeniia i taktika vedeniia bol'nykh. Astma i allergiia. 2015; 1: 19–22 (in Russian).]
7. Allergies in America: A landmark survey of nasal allergy sufferers. Executive summary. Available online at http://www.worldallergy.org/ UserFiles/file/Allergies%20in%20America%20(AIA)%20-%20Adult%20Executive%20Summary.pdf
8. Greiwe JC, Bernstein JA. Combination Therapy in Allergic Rhinitis: What Works and What Does Not Work. Am J Rhinol Allergy 2016; 30 (6): 391–6. DOI: 10.2500/ajra.2016.30.4391
9. Derendorf H, Meltzer EO. Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. Allergy 2008; 63: 1292–300. DOI: 10.1111/j.1398-9995.2008.01750.x
10. Dykewicz MS, Hamilos DL. Rhinitis and sinusitis. J Allergy Clin Immunol 2010; 125 (Suppl.): 103–S115.
11. Russell MJ, Pharm D, Dolen WK. Management of Allergic Rhinitis: A Review for the Community Pharmacist. Clin Ther, Elsevier HS J 2017; 39 (12): 1–10. DOI: 10.1016/j.clinthera.2017.10.006
12. Wheatley LM, Togias A. Clinical practice. Allergic rhinitis. New Engl J Med 2015; 372 (5): 456–63.
13. Ludger K, Annette S, Sven B. Current therapeutical strategies for allergic rhinitis. Current Therapeutical Strategies for Allergic Rhinitis. Exp Opin Pharmacother 2018; 1–7. DOI: 10.1080/14656566.2018.1543401
14. Егорова О.А. Интраназальный глюкокортикостероид флутиказона пропионат (Назарел) в лечении аллергического ринита. Атмосфера. Пульмонология и аллергология. 2010; 1: 40–4.
[Egorova O.A. Intranazal'nyi gliukokortikosteroid flutikazona propionat (Nazarel) v lechenii allergicheskogo rinita. Atmosfera. Pul'monologiia i allergologiia. 2010; 1: 40–4 (in Russian).]
15. Canonica GW, Bousquet J, Mullol J et al. A survey of the burden of allergic rhinitis in Europe. Allergy 2007; 62 (Suppl. 85): 17–25. DOI:10.1111/j.1398-9995.2007.01549.x
16. Dalal AA, Stanford R, Henry H et al. Economic burden of rhinitis in managed care: a retrospective claims data analysis. Ann Allergy Asthma Immunol 2008; 101 (1): 23–9. DOI: 10.1016/S1081-1206(10)60830-7
17. Muganurmath CS, Curry AL, Schindzielorz AH. Causality Assessment of Olfactory and Gustatory Dysfunction Associated with Intranasal Fluticasone Propionate: Application of the Bradford Hill Criteria. Adv Ther 2018; 35 (2): 173–90. DOI: 10.1007/s12325-018-0665-5
18. Ratner PH, van Bavel JH, Martin BG et al. A comparison of the efficacy of fluticasone propionate aqueous nasal spray and loratadine, alone and in combination, for the treatment of seasonal allergic rhinitis. J Fam Pract 1998; 47: 118–25.
19. Vaidyanathan S, Williamson P, Clearie K et al. Fluticasone reverses oxymetazoline-induced tachyphylaxis of response and rebound congestion. Am J Respir Crit Care Med 2010; 182: 19–24.
20. Косякова Н.И., Лягина А.А., Андреева Л.А. и др. Влияние назального спрея флутиказона на показатели местного иммунитета у пациентов с аллергическим ринитом. Педиатрич. фармакология. 2006; 1: 72–4.
[Kosiakova N.I., Liagina A.A., Andreeva L.A. et al. Vliianie nazal'nogo spreia flutikazona na pokazateli mestnogo immuniteta u patsientov s allergicheskim rinitom. Pediatrich. farmakologiia. 2006; 1: 72–4 (in Russian).]
2. Cong Li, Shen Y, Wang J et al. Increased Expression of IL-1R8 and a Possible immunomodulatory role of its ligand IL-37 in allergic rhinitis patients. Int Immunopharmacol 2018; 60 (1): 152–9. DOI: 10.1016/j.intimp.2018.04.002
3. Kurbacheva O.M., Pol'ner S.A., Smirnov D.S. Allergicheskii Rinit. Med. sovet. 2015; 3: 84–91 (in Russian).
4. Kurbacheva O.M. Allergen-spetsificheskaia immunoterapiia. Ros. allergologicheskii zhurn. 2004; 2: 32–8 (in Russian).
5. Pavlova K.S. Novye vozmozhnosti terapii allergicheskogo rinita. Atmosfera. Pul'monologiia i allergologiia. 2009; 3: 34–8 (in Russian).
6. Chichkova N. Bronkhial'naia astma i polipoznyi rinosinusit: osobennosti klinicheskogo techeniia i taktika vedeniia bol'nykh. Astma i allergiia. 2015; 1: 19–22 (in Russian).
7. Allergies in America: A landmark survey of nasal allergy sufferers. Executive summary. Available online at http://www.worldallergy.org/ UserFiles/file/Allergies%20in%20America%20(AIA)%20-%20Adult%20Executive%20Summary.pdf
8. Greiwe JC, Bernstein JA. Combination Therapy in Allergic Rhinitis: What Works and What Does Not Work. Am J Rhinol Allergy 2016; 30 (6): 391–6. DOI: 10.2500/ajra.2016.30.4391
9. Derendorf H, Meltzer EO. Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. Allergy 2008; 63: 1292–300. DOI: 10.1111/j.1398-9995.2008.01750.x
10. Dykewicz MS, Hamilos DL. Rhinitis and sinusitis. J Allergy Clin Immunol 2010; 125 (Suppl.): 103–S115.
11. Russell MJ, Pharm D, Dolen WK. Management of Allergic Rhinitis: A Review for the Community Pharmacist. Clin Ther, Elsevier HS J 2017; 39 (12): 1–10. DOI: 10.1016/j.clinthera.2017.10.006
12. Wheatley LM, Togias A. Clinical practice. Allergic rhinitis. New Engl J Med 2015; 372 (5): 456–63.
13. Ludger K, Annette S, Sven B. Current therapeutical strategies for allergic rhinitis. Current Therapeutical Strategies for Allergic Rhinitis. Exp Opin Pharmacother 2018; 1–7. DOI: 10.1080/14656566.2018.1543401
14. Egorova O.A. Intranazal'nyi gliukokortikosteroid flutikazona propionat (Nazarel) v lechenii allergicheskogo rinita. Atmosfera. Pul'monologiia i allergologiia. 2010; 1: 40–4 (in Russian).
15. Canonica GW, Bousquet J, Mullol J et al. A survey of the burden of allergic rhinitis in Europe. Allergy 2007; 62 (Suppl. 85): 17–25. DOI:10.1111/j.1398-9995.2007.01549.x
16. Dalal AA, Stanford R, Henry H et al. Economic burden of rhinitis in managed care: a retrospective claims data analysis. Ann Allergy Asthma Immunol 2008; 101 (1): 23–9. DOI: 10.1016/S1081-1206(10)60830-7
17. Muganurmath CS, Curry AL, Schindzielorz AH. Causality Assessment of Olfactory and Gustatory Dysfunction Associated with Intranasal Fluticasone Propionate: Application of the Bradford Hill Criteria. Adv Ther 2018; 35 (2): 173–90. DOI: 10.1007/s12325-018-0665-5
18. Ratner PH, van Bavel JH, Martin BG et al. A comparison of the efficacy of fluticasone propionate aqueous nasal spray and loratadine, alone and in combination, for the treatment of seasonal allergic rhinitis. J Fam Pract 1998; 47: 118–25.
19. Vaidyanathan S, Williamson P, Clearie K et al. Fluticasone reverses oxymetazoline-induced tachyphylaxis of response and rebound congestion. Am J Respir Crit Care Med 2010; 182: 19–24.
20. Kosiakova N.I., Liagina A.A., Andreeva L.A. et al. Vliianie nazal'nogo spreia flutikazona na pokazateli mestnogo immuniteta u patsientov s allergicheskim rinitom. Pediatrich. farmakologiia. 2006; 1: 72–4 (in Russian).
2. Cong Li, Shen Y, Wang J et al. Increased Expression of IL-1R8 and a Possible immunomodulatory role of its ligand IL-37 in allergic rhinitis patients. Int Immunopharmacol 2018; 60 (1): 152–9. DOI: 10.1016/j.intimp.2018.04.002
3. Курбачева О.М., Польнер С.А., Смирнов Д.С. Аллергический Ринит. Мед. совет. 2015; 3: 84–91.
[Kurbacheva O.M., Pol'ner S.A., Smirnov D.S. Allergicheskii Rinit. Med. sovet. 2015; 3: 84–91 (in Russian).]
4. Курбачева О.М. Аллерген-специфическая иммунотерапия. Рос. аллергологический журн. 2004; 2: 32–8.
[Kurbacheva O.M. Allergen-spetsificheskaia immunoterapiia. Ros. allergologicheskii zhurn. 2004; 2: 32–8 (in Russian).]
5. Павлова К.С. Новые вoзможности терапии аллергического ринита. Атмосфера. Пульмонология и аллергология. 2009; 3: 34–8.
[Pavlova K.S. Novye vozmozhnosti terapii allergicheskogo rinita. Atmosfera. Pul'monologiia i allergologiia. 2009; 3: 34–8 (in Russian).]
6. Чичкова Н. Бронхиальная астма и полипозный риносинусит : особенности клинического течения и тактика ведения больных. Астма и аллергия. 2015; 1: 19–22.
[Chichkova N. Bronkhial'naia astma i polipoznyi rinosinusit: osobennosti klinicheskogo techeniia i taktika vedeniia bol'nykh. Astma i allergiia. 2015; 1: 19–22 (in Russian).]
7. Allergies in America: A landmark survey of nasal allergy sufferers. Executive summary. Available online at http://www.worldallergy.org/ UserFiles/file/Allergies%20in%20America%20(AIA)%20-%20Adult%20Executive%20Summary.pdf
8. Greiwe JC, Bernstein JA. Combination Therapy in Allergic Rhinitis: What Works and What Does Not Work. Am J Rhinol Allergy 2016; 30 (6): 391–6. DOI: 10.2500/ajra.2016.30.4391
9. Derendorf H, Meltzer EO. Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. Allergy 2008; 63: 1292–300. DOI: 10.1111/j.1398-9995.2008.01750.x
10. Dykewicz MS, Hamilos DL. Rhinitis and sinusitis. J Allergy Clin Immunol 2010; 125 (Suppl.): 103–S115.
11. Russell MJ, Pharm D, Dolen WK. Management of Allergic Rhinitis: A Review for the Community Pharmacist. Clin Ther, Elsevier HS J 2017; 39 (12): 1–10. DOI: 10.1016/j.clinthera.2017.10.006
12. Wheatley LM, Togias A. Clinical practice. Allergic rhinitis. New Engl J Med 2015; 372 (5): 456–63.
13. Ludger K, Annette S, Sven B. Current therapeutical strategies for allergic rhinitis. Current Therapeutical Strategies for Allergic Rhinitis. Exp Opin Pharmacother 2018; 1–7. DOI: 10.1080/14656566.2018.1543401
14. Егорова О.А. Интраназальный глюкокортикостероид флутиказона пропионат (Назарел) в лечении аллергического ринита. Атмосфера. Пульмонология и аллергология. 2010; 1: 40–4.
[Egorova O.A. Intranazal'nyi gliukokortikosteroid flutikazona propionat (Nazarel) v lechenii allergicheskogo rinita. Atmosfera. Pul'monologiia i allergologiia. 2010; 1: 40–4 (in Russian).]
15. Canonica GW, Bousquet J, Mullol J et al. A survey of the burden of allergic rhinitis in Europe. Allergy 2007; 62 (Suppl. 85): 17–25. DOI:10.1111/j.1398-9995.2007.01549.x
16. Dalal AA, Stanford R, Henry H et al. Economic burden of rhinitis in managed care: a retrospective claims data analysis. Ann Allergy Asthma Immunol 2008; 101 (1): 23–9. DOI: 10.1016/S1081-1206(10)60830-7
17. Muganurmath CS, Curry AL, Schindzielorz AH. Causality Assessment of Olfactory and Gustatory Dysfunction Associated with Intranasal Fluticasone Propionate: Application of the Bradford Hill Criteria. Adv Ther 2018; 35 (2): 173–90. DOI: 10.1007/s12325-018-0665-5
18. Ratner PH, van Bavel JH, Martin BG et al. A comparison of the efficacy of fluticasone propionate aqueous nasal spray and loratadine, alone and in combination, for the treatment of seasonal allergic rhinitis. J Fam Pract 1998; 47: 118–25.
19. Vaidyanathan S, Williamson P, Clearie K et al. Fluticasone reverses oxymetazoline-induced tachyphylaxis of response and rebound congestion. Am J Respir Crit Care Med 2010; 182: 19–24.
20. Косякова Н.И., Лягина А.А., Андреева Л.А. и др. Влияние назального спрея флутиказона на показатели местного иммунитета у пациентов с аллергическим ринитом. Педиатрич. фармакология. 2006; 1: 72–4.
[Kosiakova N.I., Liagina A.A., Andreeva L.A. et al. Vliianie nazal'nogo spreia flutikazona na pokazateli mestnogo immuniteta u patsientov s allergicheskim rinitom. Pediatrich. farmakologiia. 2006; 1: 72–4 (in Russian).]
________________________________________________
2. Cong Li, Shen Y, Wang J et al. Increased Expression of IL-1R8 and a Possible immunomodulatory role of its ligand IL-37 in allergic rhinitis patients. Int Immunopharmacol 2018; 60 (1): 152–9. DOI: 10.1016/j.intimp.2018.04.002
3. Kurbacheva O.M., Pol'ner S.A., Smirnov D.S. Allergicheskii Rinit. Med. sovet. 2015; 3: 84–91 (in Russian).
4. Kurbacheva O.M. Allergen-spetsificheskaia immunoterapiia. Ros. allergologicheskii zhurn. 2004; 2: 32–8 (in Russian).
5. Pavlova K.S. Novye vozmozhnosti terapii allergicheskogo rinita. Atmosfera. Pul'monologiia i allergologiia. 2009; 3: 34–8 (in Russian).
6. Chichkova N. Bronkhial'naia astma i polipoznyi rinosinusit: osobennosti klinicheskogo techeniia i taktika vedeniia bol'nykh. Astma i allergiia. 2015; 1: 19–22 (in Russian).
7. Allergies in America: A landmark survey of nasal allergy sufferers. Executive summary. Available online at http://www.worldallergy.org/ UserFiles/file/Allergies%20in%20America%20(AIA)%20-%20Adult%20Executive%20Summary.pdf
8. Greiwe JC, Bernstein JA. Combination Therapy in Allergic Rhinitis: What Works and What Does Not Work. Am J Rhinol Allergy 2016; 30 (6): 391–6. DOI: 10.2500/ajra.2016.30.4391
9. Derendorf H, Meltzer EO. Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. Allergy 2008; 63: 1292–300. DOI: 10.1111/j.1398-9995.2008.01750.x
10. Dykewicz MS, Hamilos DL. Rhinitis and sinusitis. J Allergy Clin Immunol 2010; 125 (Suppl.): 103–S115.
11. Russell MJ, Pharm D, Dolen WK. Management of Allergic Rhinitis: A Review for the Community Pharmacist. Clin Ther, Elsevier HS J 2017; 39 (12): 1–10. DOI: 10.1016/j.clinthera.2017.10.006
12. Wheatley LM, Togias A. Clinical practice. Allergic rhinitis. New Engl J Med 2015; 372 (5): 456–63.
13. Ludger K, Annette S, Sven B. Current therapeutical strategies for allergic rhinitis. Current Therapeutical Strategies for Allergic Rhinitis. Exp Opin Pharmacother 2018; 1–7. DOI: 10.1080/14656566.2018.1543401
14. Egorova O.A. Intranazal'nyi gliukokortikosteroid flutikazona propionat (Nazarel) v lechenii allergicheskogo rinita. Atmosfera. Pul'monologiia i allergologiia. 2010; 1: 40–4 (in Russian).
15. Canonica GW, Bousquet J, Mullol J et al. A survey of the burden of allergic rhinitis in Europe. Allergy 2007; 62 (Suppl. 85): 17–25. DOI:10.1111/j.1398-9995.2007.01549.x
16. Dalal AA, Stanford R, Henry H et al. Economic burden of rhinitis in managed care: a retrospective claims data analysis. Ann Allergy Asthma Immunol 2008; 101 (1): 23–9. DOI: 10.1016/S1081-1206(10)60830-7
17. Muganurmath CS, Curry AL, Schindzielorz AH. Causality Assessment of Olfactory and Gustatory Dysfunction Associated with Intranasal Fluticasone Propionate: Application of the Bradford Hill Criteria. Adv Ther 2018; 35 (2): 173–90. DOI: 10.1007/s12325-018-0665-5
18. Ratner PH, van Bavel JH, Martin BG et al. A comparison of the efficacy of fluticasone propionate aqueous nasal spray and loratadine, alone and in combination, for the treatment of seasonal allergic rhinitis. J Fam Pract 1998; 47: 118–25.
19. Vaidyanathan S, Williamson P, Clearie K et al. Fluticasone reverses oxymetazoline-induced tachyphylaxis of response and rebound congestion. Am J Respir Crit Care Med 2010; 182: 19–24.
20. Kosiakova N.I., Liagina A.A., Andreeva L.A. et al. Vliianie nazal'nogo spreia flutikazona na pokazateli mestnogo immuniteta u patsientov s allergicheskim rinitom. Pediatrich. farmakologiia. 2006; 1: 72–4 (in Russian).
Авторы
М.Е.Дынева*, О.М.Курбачева
ФГБУ «Государственный научный центр "Институт иммунологии"» ФМБА России, Москва, Россия
*amanturliva.miramgul@mail.ru
ФГБУ «Государственный научный центр "Институт иммунологии"» ФМБА России, Москва, Россия
*amanturliva.miramgul@mail.ru
________________________________________________
Miramgul E. Dyneva*, Oksana M. Kurbacheva
National Research Center – Institute of Immunology, Moscow, Russia
*amanturliva.miramgul@mail.ru
National Research Center – Institute of Immunology, Moscow, Russia
*amanturliva.miramgul@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.